These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30871330)

  • 1. Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis.
    Akioyamen LE; Tu JV; Genest J; Ko DT; Coutin AJS; Shan SD; Chu A
    Angiology; 2019 Sep; 70(8):726-736. PubMed ID: 30871330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Barkas F; Elisaf M; Milionis H
    Atherosclerosis; 2015 Nov; 243(1):60-4. PubMed ID: 26350916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease.
    Calling S; Ji J; Sundquist J; Sundquist K; Zöller B
    Int J Cardiol; 2013 Oct; 168(3):2844-50. PubMed ID: 23642611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
    Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
    Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia.
    Kusters DM; Caceres M; Coll M; Cuffie C; Gagné C; Jacobson MS; Kwiterovich PO; Lee R; Lowe RS; Massaad R; McCrindle BW; Musliner TA; Triscari J; Kastelein JJ
    J Pediatr; 2015 Jun; 166(6):1377-84.e1-3. PubMed ID: 25841542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
    Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
    J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Akioyamen LE; Genest J; Chu A; Inibhunu H; Ko DT; Tu JV
    J Clin Lipidol; 2019; 13(1):15-30. PubMed ID: 30527766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study.
    Emanuelsson F; Nordestgaard BG; Tybjærg-Hansen A; Benn M
    J Am Coll Cardiol; 2019 Sep; 74(11):1465-1476. PubMed ID: 31514949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
    Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
    Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced global longitudinal strain at rest and inadequate blood pressure response during exercise treadmill testing in male heterozygous familial hypercholesterolemia patients.
    Vartela V; Armenis I; Leivadarou D; Toutouzas K; Makrilakis K; Athanassopoulos GD; Karatasakis G; Kolovou G; Mavrogeni S; Perrea D
    Int J Cardiol Hypertens; 2021 Jun; 9():100083. PubMed ID: 34095810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A5 gene promoter region-1131T/C polymorphism is associated with risk of ischemic stroke and elevated triglyceride levels: a meta-analysis.
    Pi Y; Zhang L; Yang Q; Li B; Guo L; Fang C; Gao C; Wang J; Xiang J; Li J
    Cerebrovasc Dis; 2012; 33(6):558-65. PubMed ID: 22688093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.